HEMATOLOGIC EFFECTS OF LOW-DOSE CONTINUOUS INFUSION INTERLEUKIN-2 WITH CONCOMITANT ALPHA-INTERFERON IN PATIENTS WITH METASTATIC SOLID MALIGNANCIES

被引：0
|
作者：
DAVE, HPG
WHITE, C
SCHULOF, R
AVIS, FP
机构：
[1] MT VERNON CANC INST,ALEXANDRIA,VA
[2] GEORGE WASHINGTON UNIV,MED CTR,DIV HEMATOL ONCOL,WASHINGTON,DC 20037
来源：
CLINICAL RESEARCH | 1991年 / 39卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：A430 / A430
页数：1
相关论文
共 50 条
  • [41] ASSOCIATION OF ALPHA-INTERFERON, INTERLEUKIN-2 AND 5-FU IN THE TREATMENT OF METASTATIC RENAL-CANCER
    ATZPODIEN, J
    PATHOLOGIE BIOLOGIE, 1994, 42 (01): : 70 - 70
  • [42] Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma
    Ellerhorst, JA
    Sella, A
    Amato, RJ
    Tu, SM
    Millikan, RE
    Finn, LD
    Banks, M
    Logothetis, CJ
    CANCER, 1997, 80 (11) : 2128 - 2132
  • [43] Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
    M J Allen
    M Vaughan
    A Webb
    S Johnston
    P Savage
    T Eisen
    S Bate
    J Moore
    R Ahern
    M E Gore
    British Journal of Cancer, 2000, 83 : 980 - 985
  • [44] A phase II study of interferon alpha and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma
    Piga, A
    Giordani, P
    Quattrone, A
    Giulioni, M
    DeSignoribus, G
    Antognoli, S
    Cellerino, R
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 44 (06) : 348 - 351
  • [45] LOW-DOSE INTERLEUKIN-2 IN THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA
    STADLER, WM
    VOGELZANG, NJ
    SEMINARS IN ONCOLOGY, 1995, 22 (01) : 67 - 73
  • [46] High dose continuous infusion VP-16, ifosfamide, solumedrol and interleukin-2 (visit) in relapsed lymphoma and refractory hematologic malignancies.
    Goodman, M
    Spector, N
    Fernandez, HF
    Cassileth, PA
    Hurley, J
    BLOOD, 1995, 86 (10) : 3240 - 3240
  • [47] EVALUATION OF TOXICITY IN 22 PATIENTS TREATED WITH SUBCUTANEOUS INTERLEUKIN-2, ALPHA-INTERFERON WITH AND WITHOUT CHEMOTHERAPY
    RIDOLFI, R
    MALTONI, R
    RICCOBON, A
    FLAMINI, E
    AMADORI, D
    JOURNAL OF CHEMOTHERAPY, 1992, 4 (06) : 394 - 398
  • [48] LOW-DOSE ALPHA-INTERFERON (RIFN-ALPHA-2B) IN HAIRY-CELL LEUKEMIA
    VONWUSSOW, P
    FREUND, M
    BLOCK, B
    DIEDRICH, H
    SCHMOLL, H
    POLIWODA, H
    DEICHER, H
    KLINISCHE WOCHENSCHRIFT, 1987, 65 (14): : 681 - 684
  • [49] DIABETES-MELLITUS IN CANCER-PATIENTS TREATED WITH COMBINATION INTERLEUKIN-2 AND ALPHA-INTERFERON
    WHITEHEAD, RP
    HAUSCHILD, A
    CHRISTOPHERS, E
    FIGLIN, R
    CANCER BIOTHERAPY, 1995, 10 (01): : 45 - 51
  • [50] EXTENDED CONTINUOUS INFUSION LOW-DOSE RECOMBINANT INTERLEUKIN-2 IN ADVANCED CANCER - PROLONGED IMMUNOMODULATION WITHOUT SIGNIFICANT TOXICITY
    CALIGIURI, MA
    MURRAY, C
    SOIFFER, RJ
    KLUMPP, TR
    SEIDEN, M
    COCHRAN, K
    CAMERON, C
    ISH, C
    BUCHANAN, L
    PERILLO, D
    SMITH, K
    RITZ, J
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (12) : 2110 - 2119
12345